Literature DB >> 24352136

A patient with HIV and tuberculosis with diminished clopidogrel response.

Nicole L Metzger1, Kathryn M Momary2.   

Abstract

Patients with HIV are at an increased risk for cardiovascular disease, both as a result of treatment with protease inhibitors and from the disease itself. The medication regimens of patients with HIV and cardiovascular comorbidities are complex and require careful assessment for potentially serious drug-drug interactions. We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction. To our knowledge, this is the first report of significant drug interactions between clopidogrel, isoniazid and ritonavir. This case underscores the importance of a detailed drug interaction screening in infectious disease patients taking complex medication regimens, including clopidogrel.
© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  AIDS; Antibiotic; HIV; antiviral; clopidogrel; drug--drug interactions; highly active antiretroviral therapy; isoniazid ritonavir

Mesh:

Substances:

Year:  2013        PMID: 24352136     DOI: 10.1177/0956462413516099

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  6 in total

Review 1.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors:  Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal:  J Med Toxicol       Date:  2015-09

2.  Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.

Authors:  Iria Bravo; Hortensia Álvarez; Ana Mariño; Bonaventura Clotet; José Moltó
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

Review 3.  Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Authors:  Zhi-Yu Wang; Meng Chen; Ling-Ling Zhu; Lu-Shan Yu; Su Zeng; Mei-Xiang Xiang; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2015-03-19       Impact factor: 2.423

4.  Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection.

Authors:  Monica M Parks; Eric A Secemsky; Robert W Yeh; Changyu Shen; Eunhee Choi; Dhruv S Kazi; Priscilla Y Hsue
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2021-05-03

5.  Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel.

Authors:  Matti K Itkonen; Aleksi Tornio; Outi Lapatto-Reiniluoto; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Journal:  Clin Pharmacol Ther       Date:  2018-08-09       Impact factor: 6.875

Review 6.  Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Authors:  Catherine Hodge; Fiona Marra; Catia Marzolini; Alison Boyle; Sara Gibbons; Marco Siccardi; David Burger; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.